Table 4.
Management and outcomes among 32 patients with human rhinovirus-associated respiratory infection during year 2012.
| Variable | Results |
|---|---|
| Place of hospitalization, n (%) | |
| General ward | 22 (68.8%) |
| Intermediate care | 9 (28.1%) |
| Intensive care | 1 (3.1%) |
| Ventilatory support | |
| Non-invasive mechanical ventilation, n (%) | 6 (18.8%) |
| Treatment, n (%) | |
| Systemic corticoids | 19 (59.4%) |
| Inhaled corticoids | 11 (34.4%) |
| Antibiotics | 29 (90.6%) |
| Antivirals (oseltamivir) | 21 (65.6%) |
| Hospital length | |
| Mean (range) in days | 11.8 (2–49) |
| ≥7 days, n (%) | 20 (62.5%) |
| Deceased, n (%) | 4 (12.5%) |